These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33917514)

  • 1. Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition.
    Park JJ; Diefenbach RJ; Byrne N; Long GV; Scolyer RA; Gray ES; Carlino MS; Rizos H
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33917514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
    Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV
    J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of metastases using circulating tumour DNA in uveal melanoma.
    Beasley AB; de Bruyn DP; Calapre L; Al-Ogaili Z; Isaacs TW; Bentel J; Reid AL; Dwarkasing RS; Pereira MR; Khattak MA; Meniawy TM; Millward M; Brosens E; de Klein A; Chen FK; Kiliҫ E; Gray ES
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14953-14963. PubMed ID: 37608028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma.
    de Bruyn DP; van Poppelen NM; Brands T; van den Boom SC; Eikenboom E; Wagner A; van Veghel-Plandsoen MM; Geeven G; Beverloo B; van Rij CM; Verdijk RM; Naus NC; Bagger MM; Kiilgaard JF; de Klein A; Brosens E; Kiliç E
    Invest Ophthalmol Vis Sci; 2024 Feb; 65(2):11. PubMed ID: 38319670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma.
    Beasley A; Isaacs T; Khattak MA; Freeman JB; Allcock R; Chen FK; Pereira MR; Yau K; Bentel J; Vermeulen T; Calapre L; Millward M; Ziman MR; Gray ES
    JCO Precis Oncol; 2018; 2():. PubMed ID: 32913999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.
    Serrano C; Vivancos A; López-Pousa A; Matito J; Mancuso FM; Valverde C; Quiroga S; Landolfi S; Castro S; Dopazo C; Sebio A; Virgili AC; Menso MM; Martín-Broto J; Sansó M; García-Valverde A; Rosell J; Fletcher JA; George S; Carles J; Arribas J
    BMC Cancer; 2020 Feb; 20(1):99. PubMed ID: 32024476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors - Results of a Prospective Biomarker Study.
    Forschner A; Weißgraeber S; Hadaschik D; Schulze M; Kopp M; Kelkenberg S; Sinnberg T; Garbe C; Biskup S; Battke F
    Onco Targets Ther; 2020; 13():5017-5032. PubMed ID: 32581559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.
    Chang GA; Tadepalli JS; Shao Y; Zhang Y; Weiss S; Robinson E; Spittle C; Furtado M; Shelton DN; Karlin-Neumann G; Pavlick A; Osman I; Polsky D
    Mol Oncol; 2016 Jan; 10(1):157-65. PubMed ID: 26440707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma.
    Kim C; Xi L; Cultraro CM; Wei F; Jones G; Cheng J; Shafiei A; Pham TH; Roper N; Akoth E; Ghafoor A; Misra V; Monkash N; Strom C; Tu M; Liao W; Chia D; Morris C; Steinberg SM; Bagheri H; Wong DTW; Raffeld M; Guha U
    Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283064
    [No Abstract]   [Full Text] [Related]  

  • 10. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
    Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
    JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
    Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
    Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma.
    Wong SQ; Raleigh JM; Callahan J; Vergara IA; Ftouni S; Hatzimihalis A; Colebatch AJ; Li J; Semple T; Doig K; Mintoff C; Sinha D; Yeh P; Silva MJ; Alsop K; Thorne H; Bowtell DD; Gyorki DE; Arnau GM; Cullinane C; Kee D; Brady B; Kelleher F; Dawson MA; Papenfuss AT; Shackleton M; Hicks RJ; McArthur GA; Sandhu S; Dawson SJ
    JCO Precis Oncol; 2017 Nov; 1():1-14. PubMed ID: 35172485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
    Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
    PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients.
    Di Nardo L; Del Regno L; Di Stefani A; Mannino M; Fossati B; Catapano S; Quattrini L; Pellegrini C; Cortellini A; Parisi A; Capoluongo E; Autilio C; Fargnoli MC; Peris K
    Exp Dermatol; 2023 Oct; 32(10):1785-1793. PubMed ID: 37533342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
    Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
    Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
    Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 18. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.
    Diefenbach RJ; Lee JH; Menzies AM; Carlino MS; Long GV; Saw RPM; Howle JR; Spillane AJ; Scolyer RA; Kefford RF; Rizos H
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32785074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma.
    Braune J; Keller L; Schiller F; Graf E; Rafei-Shamsabadi D; Wehrle J; Follo M; Philipp U; Hussung S; Pfeifer D; Mix M; Duyster J; Fritsch R; von Bubnoff D; Meiss F; von Bubnoff N
    JCO Precis Oncol; 2020 Nov; 4():20-31. PubMed ID: 35050727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.